Authors

• K. Yamaguchi
• Ari Gnanasakthy (ORCID: https://orcid.org/0000-0001-9176-3983)
• I. Majer
• Yoon‐Koo Kang (ORCID: https://orcid.org/0000-0003-0783-6583)
• K. Taylor
• Zev A. Wainberg (ORCID: https://orcid.org/0000-0002-7142-1246)
• P.C. Enzinger
• Akeem Yusuf (ORCID: https://orcid.org/0000-0002-0001-1311)
• Aurélien Jamotte (ORCID: https://orcid.org/0000-0003-2274-4361)
• Shukui Qin (ORCID: https://orcid.org/0000-0003-2289-1521)
• Xuan Zhou (ORCID: https://orcid.org/0000-0003-3919-0342)
• Jinyi Wang (ORCID: https://orcid.org/0000-0001-6013-1422)

Institutions

• Ulsan College (KR)
• Amgen (United States) (US)
• University of California, Los Angeles (US)
• China Pharmaceutical University (CN)
• University of Ulsan (KR)
• Triangle (US)
• Los Angeles Medical Center (US)
• Dana-Farber Cancer Institute (US)
• Amgen (United Kingdom) (GB)
• RTI Health Solutions (US)
• The Cancer Institute Hospital (JP)
• Amgen (Switzerland) (CH)

Publication Details

Journal

ESMO Gastrointestinal Oncology

Published

2024-10-08

DOI

https://doi.org/10.1016/j.esmogo.2024.100095

Citations

1

Primary Topic

Fibroblast Growth Factor Research

Type

article

Field-Weighted Citation Impact

0.23

Funders

• Amgen